WO2004002973A1 - 光学活性1−置換アミノー2,3−エポキシプロパンの製造方法並びにその合成中間体およびそれらの製造方法 - Google Patents
光学活性1−置換アミノー2,3−エポキシプロパンの製造方法並びにその合成中間体およびそれらの製造方法 Download PDFInfo
- Publication number
- WO2004002973A1 WO2004002973A1 PCT/JP2003/007695 JP0307695W WO2004002973A1 WO 2004002973 A1 WO2004002973 A1 WO 2004002973A1 JP 0307695 W JP0307695 W JP 0307695W WO 2004002973 A1 WO2004002973 A1 WO 2004002973A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- optically active
- general formula
- atom
- reaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
- C07D301/02—Synthesis of the oxirane ring
- C07D301/24—Synthesis of the oxirane ring by splitting off HAL—Y from compounds containing the radical HAL—C—C—OY
- C07D301/26—Y being hydrogen
Definitions
- the present invention relates to a method for producing an optically active mono-substituted amino_2,3-epoxypropane, a synthetic intermediate thereof, and a method for producing them.
- the present invention relates to a method for producing optically active mono-substituted amino 2,3-epoxypropane, a synthetic intermediate thereof, and a method for producing them, which are useful as intermediates for producing agricultural chemicals and pharmaceuticals.
- Optically active mono-substituted amino-2,3-epoxypropanes can be used, for example, in the HIV proteazyme, pp. 37-22, Journal of Medicinal Chemistry [Journal of the Medicinal Chemistry]. , 3707 (1994)], and is extremely useful as an intermediate of an antibacterial agent having a dioxazolidinone skeleton (WO 02Z32857 pamphlet).
- the regioselectivity in the primary hydroxyl group selective tosylation of 1,2-diol is not perfect, and only the secondary hydroxyl group is tosylated, or both hydroxyl groups are tosylated.
- the yield and optical purity of the produced amino-epoxypropane derivative are reduced.
- the yield of the desired product is not good because the method is basically optical resolution, and the formation of several types of by-products has been recognized. There are problems with these efficient separations. In addition, the production of highly dangerous azide derivatives during the production process is also an industrial problem.
- the method of (3) is not an industrially advantageous production method because it involves a large number of production steps and uses an acetyl-azide derivative which is highly dangerous during the production.
- the problem with the method (4) is that the synthesis of the optically active 1-amino-3-chloro-2-propanol hydrochloride of the raw material is multi-step.
- An object of the present invention is to provide a method for producing an optically active mono-substituted amino-2,3-epoxypropane which is efficient and economical and can be industrially preferably carried out in view of the above situation. It is assumed that. Disclosure of the invention
- a first aspect of the present invention provides a compound represented by general formula (1):
- R 3 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an aryl group having 6 to 10 carbon atoms or an aralkyl group having 7 to 10 carbon atoms which may be substituted, and R 4 represents a carbon atom.
- R 3 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an aryl group having 6 to 10 carbon atoms or an aralkyl group having 7 to 10 carbon atoms which may be substituted
- R 4 represents a carbon atom.
- Y represents a halogen atom or a lower alkoxy group.
- * represents an asymmetric carbon atom or an asymmetric sulfur atom
- A represents a carbon atom or a sulfur atom
- B 1 represents a group R 3 (R 3 has the same meaning as described above)
- B represents 2 is the group OR 4
- the second present invention provides an optically active 1-substituted amino-2,3-propanediol represented by the general formula (1) with a compound represented by the general formula (2) or a compound represented by the general formula (3).
- a third aspect of the present invention is an optically active compound (4).
- a fourth invention is a method for producing an optically active compound (5), comprising ring-opening the optically active compound represented by the general formula (4).
- the fifth present invention provides an optically active mono-substituted amino-2,3-propanediol represented by the general formula (1) with a compound represented by the general formula (2) or a compound represented by the general formula (3):
- the method is also a method for producing an optically active compound (5), which comprises reacting the compound with the compound represented by the formula (1) to produce an optically active compound (4), followed by ring opening.
- the present invention provides a step of converting an optically active mono-substituted amino-2,3-propanediol represented by the general formula (1) into an optically active compound represented by the general formula (4), Step of ring-opening and converting to optically active compound represented by general formula (5) And the step of ring-closing the optically active compound (5) to convert it into the optically active 1-substituted amino_2,3-epoxypropane represented by the general formula (6).
- Each step will be described.
- the optically active mono-substituted amino-1,2,3-propanediol represented by the general formula (1), which is the starting material, is converted into the optically active compound (4).
- the starting raw material compound (1) Will be described.
- the compound (1) that is, the optically active 1-substituted amino-2,3-propanediol
- the compound (1) can be prepared according to a known method, for example, by adding the optically active 1-chloro-2,3-propanediol to ammonium chloride in the presence of ammonium chloride. By reacting with ammonia water, it is converted to optically active 1-amino-2,3-propanediol (JP-A-3-41056), and the amino group is subsequently protected, or optically active glycerol is converted to the protected acetonide.
- optically active 1-chloro-2,3-propanediol can have any configuration of (R) or (S). Therefore, the optically active 1-chloro-2,3-propanediol can be represented by the general formula (1) produced above.
- the configuration of the optically active 1-substituted amino-2,3_propanediol used is either (R) or (S), and the optically active 1-substituted amino represented by the general formula (1) in both configurations — 2, 3-propanediol is included in the scope of the present invention.
- RR 2 is different from each other, and is a hydrogen atom or a olebamate type.
- a sil-based or arylo-based amino-protecting group, or RR 2 taken together represents an imido-based amino-protecting group.
- amino acid-protecting group of the olebamate group examples include a methoxycarbonyl group, an ethoxycarbonyl group, an n-propoxycarbonyl group, an isopropoxycarbonyl group, a t-butoxycarbonyl group, a pentyloxycarbonyl group, and an isopentyloxycarbonyl group.
- amide-based amino protecting group examples include formyl group, acetyl group, propionyl group, butyryl group, bivaloyl group, 2-chloroacetyl group, 2-bromoacetyl group, 2-odoacetyl group and 2,2-dichloroacetyl group. Is done.
- Examples of the aroyl-based amino-protecting group include a benzoyl group, a 4-methoxybenzoyl group, a 3-hydroxy-2-methylbenzoyl group, a 3-acetoxy_2-methylbenzoyl group, a 4-nitrobenzoyl group, and a naphthylcarbonyl group. . Phthaloyl group, tetrachloro phthaloyl group And 412 trophthaloyl groups.
- methoxycarbonyl group, ethoxycarbonyl group, t-butoxycarbonyl group, benzyloxycarbonyl group, acetyl group, benzoyl group, and phthaloyl group are preferred.
- Preferred are t-butoxycarbonyl, benzyloxycarbonyl, benzoyl and phthaloyl.
- the compound (1) is an intermediate compound which is a preferable intermediate compound for producing the optically active 1-substituted amino-2,3-epoxypropane represented by the general formula (6), which is the target compound of the present invention. Converted to the active compound (4).
- This conversion reaction is carried out, for example, by reacting the compound (1) with a compound represented by the general formula (2) or a compound represented by the general formula (3).
- R 3 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an aryl group having 6 to 10 carbon atoms, or is substituted. Represents an aralkyl group having 7 to 10 carbon atoms which may be linear, branched or cyclic.
- alkyl group examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and t-alkyl groups having 1 to 6 carbon atoms. Butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, etc .;
- Examples of the aryl group having 6 to 10 carbon atoms include a phenyl group, a 4-methylphenyl group, a 2,4,6-trimethylphenyl group, a 1-naphthyl group, and a 2-naphthyl group;
- Examples of the aralkyl group include a benzyl group, a 1-phenethyl group, a 2_phenethyl group, and a 1- (4-methoxyphenyl) ethyl group.
- R 4 represents an alkyl group having 1 to 6 carbon atoms, and these groups may be any of linear, branched or cyclic.
- examples of such a substance include, but are not particularly limited to, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a t-butyl group, a pentyl group, a cyclopentyl group, a hexyl group, And a cyclohexyl group.
- a methyl group and an ethyl group are preferred in view of the availability of the compound (2) and the like.
- particularly preferred compounds represented by the general formula (2) are orthoformate, orthoacetate, orthopropionate, orthobutyrate, and orthobenzoate. More specifically, Trimethyl orthoformate, Triethyl orthoformate, Trimethyl orthoacetate, Triethyl orthoacetate, Trimethyl orthopropionate, Triethyl orthopropionate, Trimethyl orthobutyrate, Triethyl orthobutyrate, Trimethyl orthobenzoate, Triethyl orthobenzoate.
- optically active 1-substituted amino-2,3-propanediol represented by the general formula (1) described above is produced by reacting the compound represented by the general formula (2) with the compound represented by the general formula (4) that a of the optically active compounds represents a carbon atom, an 8 1 Motoshaku 3, B 2 represents a group oR 4, with respect to R 3 and R 4, it is already as described above. Also, with respect to RR 2, but as explained above, in order to obtain later-described optically active compound (5) in good yield is, one of the RR 2 is Ri Oh a hydrogen atom, the other one Is particularly preferably a carbamate-based amino protecting group.
- the optically active compound (4) is a novel compound.
- the optically active compound (4) is formed by the reaction of the compound (1) with the compound (2), one new asymmetric carbon atom is generated, but the stereoselectivity at this time is generally poor, and , (R) or (S) each of the two asymmetric carbon atoms having the configuration Generated without much bias toward the direction.
- the reaction for producing the optically active compound represented by the above general formula (4) is carried out in the presence of an acid catalyst.
- the acid catalyst to be used is not particularly limited, but may be a protonic acid, a salt of a protonic acid and an amine, Lewis Acids and the like can be suitably used.
- protic acids include hydrogen octogene such as hydrogen chloride, hydrogen bromide, and hydrogen iodide; inorganic acids such as sulfuric acid, phosphoric acid, perchloric acid, and borofluoric acid; methanesulfonic acid; benzenesulfonic acid; Organic or inorganic sulfonic acids such as p-toluenesulfonic acid, trifluoromethanesulfonic acid, camphorsulfonic acid, chlorosulfonic acid, formic acid, acetic acid, butyric acid, chloroacetic acid, dichloroacetic acid, trichloroacetic acid, bromoacetic acid, dibromoacetic acid, Organic carboxylic acids such as trifluoroacetic acid, glycolic acid, oxalic acid, succinic acid, benzoic acid and salicylic acid can be mentioned.
- hydrogen octogene such as hydrogen chloride, hydrogen bromide, and hydrogen iod
- a salt of a protonic acid with an amine a salt of a strong protonic acid such as hydrogen halide or sulfonic acid with an amine is preferable.
- amine in addition to aliphatic primary amine, secondary amine, tertiary amine, ammonia , A complex ring amine and the like.
- ammonium chloride ammonium bromide, ammonium sulfate, ammonium nitrate, pyridine-P-toluenesulfonate, quinolin-P-toluenesulfonate, triethylamine-sulfate, triethylamine-hydrochloride , Pyridine-hydrochloride, imidazo monohydrochloride, methylamine-sulfate, dimethylamine-sulfate, pyridine-sulfate, lutidine monosulfate, collidine-sulfate, pyridine-trifluoromethanesulfonate, pyridine-trifluorobenzoate Acid salt, pyridine monotric acid acetate and the like.
- a salt may be used, or the salt may be prepared by mixing the protonic acid and the amine in a reaction system.
- Lewis acids include zinc chloride, zinc bromide, zinc iodide, aluminum chloride, aluminum bromide, boron trifluoride monoether complex, stannic chloride, ferric chloride, titanium tetrachloride, and the like.
- a cation exchange resin such as Dowex 50 or a solid acid such as silica gel, polyphosphoric acid or phosphorus pentoxide can be used as a catalyst.
- acetic acid p-toluenesulfonic acid, pyridine-p-toluenesulfonic acid salt, triethylamine-sulfate, zinc chloride or zinc bromide is particularly preferred.
- the amount of the acid used is not particularly limited, but usually the lower limit is 0.0 lmo 1% based on the optically active 1-substituted amino-2,3-propanediol represented by the general formula (1),
- the upper limit can be implemented at 100% Omo. From the viewpoint of reaction rate and economy, a preferred lower limit is 0.1 mol 1%, and a preferred upper limit is 1 mol 1%.
- the amount of the compound (2) used for the optically active 1-substituted amino-2,3-propanediol represented by the general formula (1) is usually used in excess, and the lower limit is 100 mol%.
- the upper limit is 50 Omo 1%, but a preferable lower limit is 105 Omo 1% and a preferable upper limit is 30 Omo 1% from the viewpoint of reaction speed and economy.
- a solvent is usually used in the above reaction, and the solvent used is not particularly limited as long as it does not inhibit the reaction.
- the solvent include fats such as heptane, hexane, cyclohexane, and methylcyclohexane.
- the amount of the solvent used is not particularly limited, but the lower limit is the amount of lm 1 Zg with respect to the optically active 1-substituted amino-1,2,3-propanediol represented by the general formula (1).
- the upper limit is the quantity at 100 m 1 Z g. In consideration of the operability and economics of the reaction, a preferred lower limit is the amount of 2 m1Zg, and a preferred upper limit is the amount of 3Om1Zg.
- the reaction temperature varies depending on the type of the solvent used and the type of the acid catalyst, but usually, an arbitrary temperature in a range from the freezing point to the boiling point of the reaction solvent can be selected.
- the lower limit is —20 and the upper limit is 150.
- a preferred lower limit is 0 and a preferred upper limit is 115.
- the reaction time varies depending on the type of compound (2) used, the type of acid catalyst, the reaction solvent and the reaction temperature, but is usually about 0.5 to 82 hours.
- the degree of progress of the reaction can be confirmed by a time-dependent analysis of the reaction solution using ordinary analytical means, for example, high performance liquid chromatography (HPLC), and the optical activity represented by the general formula (1)
- HPLC high performance liquid chromatography
- the end point of the reaction can be determined from the disappearance of the 1-substituted amino-2,3-propanediol.
- the post-treatment method of the above reaction is not particularly limited. After the reaction, for example, ammonia water or water is added to the reaction solution to stop the reaction, and ethyl acetate, toluene, benzene, getyl ether, dichloromethane, etc.
- the desired product can be extracted by extracting the desired product with an appropriate organic solvent, washing the extracted layer with water or saturated saline, concentrating the solvent, and the like.
- the target product may be isolated as a concentrate by simply distilling the reaction solvent from the reaction solution under reduced pressure.
- the reaction solvent containing the target product may be isolated by concentrating and distilling the reaction solvent partially. May be used as a solution in the next step. If necessary, for example, separation and purification by column chromatography may be performed.
- Y represents a halogen atom or a lower alkoxy group.
- halogen atom a fluorine atom, a chlorine atom , A bromine atom and an iodine atom.
- the lower alkoxy group include a methoxy group, an ethoxy group, an n-propoxy group, Examples include an isopropoxy group, an n-butoxy group, a sec-butoxy group, and a t-butoxy group.
- the halogen atom is a chlorine atom or a bromine atom
- the lower alkoxy group is a methoxy group, an ethoxy group, an n-propoxy group, or an isopropoxy group because of the availability of the compound (3). is there.
- the compounds represented by the general formula (3) include thionyl fluoride, thionyl chloride, thionyl bromide, thionyl iodide, dimethyl sulfite, getyl sulfite, di-n-propyl sulfite, diisopropyl sulfite, and di-n-butyl sulfite. And di-tert-butyl sulfite and di-t-butyl sulfite.
- thionyl chloride thionyl bromide
- dimethyl sulfite getyl sulfite, di-n-propyl sulfite, and diisopropyl sulfite.
- the optically active 1-substituted amino-2,3-propanediol represented by the general formula (1) described above is produced by reacting the compound represented by the general formula (3) with the compound represented by the general formula (4) A in the optically active compound represents a sulfur atom, and B 1 and B 2 together represent an oxygen atom.
- the RR 2 is as described above.
- RR 2 is different from each other and is a hydrogen atom or an amino-protecting group such as a rubamate-type, an acyl-type or an aroyl-type, the optically active compound (4) Is a new compound.
- a novel optically active compound (4) is described in, for example, HIV protease inhibitor [Journa 1 of the Medicinal Chemistry], Vol. 37, No. 22, 3707 (1994)], and an intermediate of an antibacterial agent having an oxazolidinone skeleton (WO 02/32857 pamphlet), and the like. Further, the production of the optically active compound (4), which is a novel compound, makes it possible to efficiently and industrially advantageously produce the optically active monosubstituted amino-2,3-epoxypropane represented by the general formula (6). it can.
- optically active compound (4) is formed by the reaction of the compound (1) with the compound (3), one new asymmetric sulfur atom is generated, and the stereoselectivity at this time is generally low. Poor, and therefore, asymmetric sulfur atoms with (R) or (S) configuration Are generated without being biased toward one or the other. That is, when an optically pure (R) or (S) optically active 1-substituted amino-2,3-propanediol represented by the general formula (1) is used, almost the same amount of diol is used.
- a mixture of diastereomers of different species can also be produced using optically pure (R) or (S) optically active 1-substituted amino-2,3-propanediol of the general formula (1)
- R optically pure
- S optically active 1-substituted amino-2,3-propanediol of the general formula (1)
- a mixture of four diastereomers is formed in a form reflecting the optical purity of the optically active monosubstituted amino-2,3-propanediol represented by the general formula (1). Is also included as an object of the present invention.
- the amount of the compound (3) used relative to the optically active 1-substituted amino-2,3-propanediol represented by the general formula (1) is usually used in excess, and the lower limit is 10 Omo 1% and the upper limit is Is 100% Omo, but from the viewpoint of reaction speed and economy, a preferable lower limit is 105% Mo1% and a preferable upper limit is 30% Omo1%.
- a solvent is usually used in the above reaction, and the solvent used is not particularly limited as long as it does not inhibit the reaction.
- the solvent include fats such as heptane, hexane, cyclohexane, and methylcyclohexane.
- Aromatic or alicyclic hydrocarbon solvents aromatic hydrocarbon solvents such as benzene, toluene, xylene, etc., ether solvents such as getyl ether, diisopropyl ether, methyl t-butyl ether, tetrahydrofuran, dioxane, methyl acetate, acetic acid Ester solvents such as ethyl and butyl acetate; ketone solvents such as acetone and ethyl methyl ketone; halogenated hydrocarbons such as methylene chloride, 1,2-dichloroethane, chloroform, carbon tetrachloride, and cyclobenzene.
- aromatic hydrocarbon solvents such as benzene, toluene, xylene, etc.
- ether solvents such as getyl ether, diisopropyl ether, methyl t-butyl ether, tetrahydrofuran, diox
- Lil solvents N, N-dimethylformamide, N, N-dimethyl ⁇ Seto amide and the like, may be used by mixing two or more kinds of the above solvents.
- toluene and methylene chloride are frequently used.
- the above reaction can be carried out as a solventless reaction without using a solvent.
- the use amount of the above solvent is not particularly limited, but the lower limit is the amount of lm 1 Zg with respect to the optically active mono-substituted amino-2,3-propanediol represented by the general formula (1),
- the upper limit is the quantity of 100 m 1 Z g.
- a preferred lower limit is an amount of 2 m 1 / g
- a preferred upper limit is an amount of 30 m 1.
- Y is a halogen atom
- amine or the like may be added to neutralize the hydrogen halide generated by the reaction, but the above reaction can be carried out without the addition.
- a functional group which is weak to hydrogen halide generated in the optically active 1-substituted amino-2,3-propanediol represented by the general formula (1) is present, addition of an amine or the like is preferable.
- the amine to which the amine is added is not particularly limited, but is preferably a tertiary amine such as trimethylamine, triethylamine, or tripropylamine, or pyridine.
- the lower limit of the addition amount of the above amine is 200 mo 1% and the upper limit is 200 Omo 1% based on the compound represented by the general formula (1). Considering economics, a preferred lower limit is 20 Omo 1%, and a preferred upper limit is 60 Omo 1%.
- an acid catalyst or a base catalyst may be added as necessary.
- the acid catalyst include organic sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid, and camphorsulfonic acid.
- the base include lithium-t-butoxide and sodium-t-butoxide.
- the lower limit of the catalyst is lmol% based on the optically active mono-substituted amino-2,3-propanediol represented by the general formula (1), and the upper limit is 5 Omo 1 %, A preferred lower limit is lmo 1%, and a preferred upper limit is 25 mo 1%.
- the lower limit is lmo 1%
- the upper limit is 5 Omo 1%
- the preferred lower limit is lmo 1%
- the preferred upper limit is 1 Omo 1%.
- the reaction temperature varies depending on the type of the solvent used and the type of the acid catalyst, but usually, an arbitrary temperature in a range from the freezing point to the boiling point of the reaction solvent can be selected. Generally, the lower limit is 0 ° C and the upper limit is 150. The preferred lower limit is Ot: A good upper limit is 50.
- the reaction time varies depending on the kind of the optically active 1-substituted amino-2,3-propanediol represented by the general formula (1) and the compound (3) or the reaction solvent and the reaction temperature, but is usually 0.5 to 24 hours. It is about.
- the progress of the reaction can be confirmed by the time-dependent analysis of the reaction solution using ordinary analytical means, for example, high performance liquid chromatography (HPLC), and the optical activity represented by the general formula (1) is obtained.
- HPLC high performance liquid chromatography
- the end point of the reaction can be determined from the disappearance of the 1-substituted amino-2,3-propanediol.
- the post-treatment method for the above reaction is not particularly limited.
- the target product can be isolated by extracting the desired product, washing the extracted layer with water, a dilute aqueous hydrochloric acid solution or saturated saline, concentrating the solvent, and the like.
- the target product may be isolated as a concentrate by simply distilling the reaction solvent from the reaction solution under reduced pressure. If necessary, for example, separation and purification by column chromatography may be performed. Next, the second step will be described.
- the optically active compound represented by the general formula (4) obtained as described above is converted into an optically active compound represented by the general formula (5) by ring opening.
- the ring opening reaction to be performed is different. Therefore, each case will be described below.
- compound (4) is obtained by reacting compound (1) with compound (2).
- X represents a halogen atom, and includes, for example, a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, and is preferably a chlorine atom or a bromine atom.
- Scale 5 represents a group ⁇ OR 3, for R 3 are as already described above.
- R 1 As for R 2 in order to obtain the optically active compound (5) at a high yield, one of RR 2 is a hydrogen atom, and the other is a carbonyl-based compound. Particularly preferred are amino protecting groups.
- an optically active compound (5) is a novel compound.
- the optically active compound represented by the general formula (5) has one asymmetric carbon atom, its configuration is different from that of the corresponding asymmetric carbon atom of the optically active compound represented by the general formula (4). Since the asymmetric carbon atom does not participate in the ring-opening reaction in this step, the configuration of the corresponding asymmetric carbon atom of the optically active compound represented by the general formula (4) is Does not change and is inherited by the configuration of the asymmetric carbon atom of the optically active compound represented by the general formula (5).
- Examples include phosphorus, trityl chloride, hydrogen chloride, hydrogen bromide monoacetic acid solution, and getylaminosulfur art fluoride (DAST).
- Preferred are trimethylsilyl chloride, acetyl chloride, thionyl chloride, sulfuryl chloride, phosphorus pentachloride, phosphorus oxy
- the optically active compound represented by the general formula (4) and / or the optically active compound represented by the general formula (5) is a compound sensitive to an acid
- a base such as triethylamine may be used in an amount of up to 1%.
- the decomposition of the optically active compound represented by the general formula (4) and the optically active compound represented by the general formula (5) or Z during the ring opening reaction is suppressed.
- the reaction can be carried out such that the reaction proceeds with good yield.
- the reaction rate is low, the reaction rate is increased by adding a Lewis acid such as zinc chloride, zinc bromide, tin bromide, or sodium iodide. May be able to.
- the lower limit of the amount of the ring-opening reaction reagent used is 10 Omo 1% and the upper limit is 50 Omo 1% based on the optically active compound represented by the general formula (4).
- a preferred lower limit is 110 mol 1%, and a preferred upper limit is 150 mol 1%.
- a solvent is usually used in the above reaction, and the solvent used is not particularly limited as long as it does not inhibit the reaction.
- the solvent include fatty acids such as heptane, hexane, cyclohexane, and methylcyclohexane.
- Aromatic or alicyclic hydrocarbon solvents aromatic hydrocarbon solvents such as benzene, toluene, xylene, etc., ether solvents such as getyl ether, diisopropyl ether, methyl t-butyl ether, methyl acetate, ethyl acetate, butyl acetate Ester solvents such as acetone, ketone solvents such as acetone and ethyl methyl ketone; halogenated hydrocarbon solvents such as methylene chloride, 1,2-dichloroethane, chloroform, carbon tetrachloride, and chlorobenzene; acetonitrile, propionitrile And nitrile solvents such as benzonitrile; A mixture of two or more serial solvents may be used.
- the reaction solvent used in this step may be the solvent used in the production of the optically active compound represented by the general formula (4) in the previous step, or may be used as a different solvent.
- the solvent used at the time of producing the optically active compound represented by the general formula (4) is preferably used as it is in view of process efficiency and economy.
- toluene and methylene chloride are preferably used frequently.
- the amount of the solvent used is not particularly limited, but the lower limit is the amount of lm 1 / g and the upper limit is the amount of 10 O m 1 for the optically active compound represented by the general formula (4). It is. In consideration of the operability and economy of the reaction, a preferred lower limit is the amount of 2 mlZg, and a preferred upper limit is the amount of 2 Om1 / g.
- the reaction temperature varies depending on the type of the solvent used and the type of the optically active compound represented by the general formula (4), but usually, any temperature in the range from the freezing point to the boiling point of the reaction solvent can be selected. Generally, the lower limit is 1 20 and the upper limit is 150. A preferred lower limit is 0, and a preferred upper limit is 1 15.
- the reaction time depends on the type of optically active compound represented by the general formula (4) used, the reaction solvent, and the like. Although it depends on the reaction temperature and the reaction temperature, it is usually about 0.5 to 72 hours.
- the degree of progress of the reaction can be confirmed by analyzing the reaction solution over time using ordinary analytical means, for example, high performance liquid chromatography (HPLC), and the optical activity represented by the general formula (4) can be confirmed.
- HPLC high performance liquid chromatography
- the disappearance of the compound indicates the end point of the reaction.
- the post-treatment method for the above reaction is not particularly limited. After the reaction, for example, a saturated sodium bicarbonate solution is added while cooling the reaction solution as necessary to stop the reaction, and ethyl acetate, toluene, benzene, getyl ether are added.
- the desired product can be isolated by extracting the desired product with an appropriate organic solvent such as dichloromethane or the like, washing the extracted layer with water or saturated saline, concentrating the solvent, and the like.
- the target product may be isolated as a concentrate by simply distilling the reaction solvent from the reaction solution under reduced pressure.
- the reaction solvent containing the target product may be isolated by partially evaporating the reaction solvent.
- the solution may be used in the next step. If necessary, separation and purification by column chromatography may be performed.
- the optically active compound represented by the general formula (5) has one asymmetric carbon atom, its configuration is different from that of the corresponding asymmetric carbon atom of the optically active compound represented by the general formula (4). Since the asymmetric carbon atom does not participate in the ring-opening reaction in this step, as in the case described above, the optically active compound represented by the general formula (4) The configuration is taken over by the configuration of the asymmetric carbon atom of the optically active compound represented by the general formula (5) without changing the configuration of the corresponding asymmetric carbon atom.
- reagent used in the ring-opening reaction in this step one having the ability to cause a substitution reaction on the optically active compound represented by the general formula (4) to introduce a halogen atom X is used.
- the lower limit of the amount of the ring-opening reaction reagent used is 10 Omo 1% and the upper limit is 150 Omo 1% based on the optically active compound represented by the general formula (4).
- a preferred lower limit is 15 Omo 1%, and a preferred upper limit is 60 Omo 1%.
- a solvent is usually used in the above reaction, and the solvent used is not particularly limited as long as it does not inhibit the reaction. Examples thereof include getyl ether, diisopropyl ether, methyl t-butyl ether, and tetrahydrofuran.
- aprotic polar solvents such as acetone, tetrahydrofuran, 1,2-dimethoxyethane, acetonitrile, N, N-dimethylformamide and the like are frequently used.
- the amount of the solvent used is not particularly limited, but the lower limit is the amount of lm 1 and the upper limit is the amount of 10 O m 1 for the optically active compound represented by the general formula (4). .
- a preferred lower limit is the amount of 2 mlg
- a preferred upper limit is the amount of 2Om1Zg.
- the reaction temperature varies depending on the type of the solvent used and the type of the optically active compound represented by the general formula (4), but usually, any temperature in the range from the freezing point to the boiling point of the reaction solvent can be selected. Generally, the lower limit is —20 and the upper limit is 180. A preferred lower limit is 30 and a preferred upper limit is 150.
- the reaction time varies depending on the type of the optically active compound represented by the general formula (4) used, the reaction solvent and the reaction temperature, but is usually about 0.5 to 40 hours.
- the degree of progress of the reaction can be determined by ordinary analytical means such as high-performance liquid chromatography. It can be confirmed by analyzing the reaction solution over time using Raffy (HPLC), and the end point of the reaction can be known from the disappearance of the optically active compound represented by the general formula (4).
- the post-treatment method for the above reaction is not particularly limited. After the reaction, for example, if necessary, the reaction is stopped by adding a dilute hydrochloric acid aqueous solution, and an appropriate solution such as ethyl acetate, toluene, benzene, getyl ether, dichloromethane or the like is added.
- the desired product can be isolated by extracting the desired product with an organic solvent, washing the extracted layer with water or saturated saline, concentrating the solvent, and the like. If necessary, separation and purification by column chromatography may be performed. Finally, the third step will be described.
- the optically active compound represented by the general formula (5) obtained as described above is converted into an optical compound represented by the general formula (6), which is the target compound of the present invention, by ring closure.
- Active 1 Converted to monosubstituted amino-2,3-epoxypropane.
- R 5 in compound (5) treated in this step represents a formyl group, an acyl group, or an aroyl group, and may be both a COR 3 group and a hydrogen atom.
- the ring closure reaction is performed in the presence of a base.
- the optically active mono-substituted amino-2,3-epoxypropane represented by the general formula (6) obtained in this step will be described.
- the R 1 R 2 in the compound (6) is as described above, but when the compound (6) is regarded as an intermediate for the production of an optically active drug, particularly preferable RR 2 is RR 2
- One is a hydrogen atom and the other is a t-butoxycarbonyl group, a benzyloxycalponyl group, or a benzoyl group, or RR 2 together is a fluoryl group.
- the 1-substituted amino-2,3 epoxypropane represented by the general formula (6) has one asymmetric carbon atom, and its configuration is represented by the optically active compound represented by the general formula (5). Is derived from the configuration of the corresponding asymmetric carbon atom. In general, the configuration does not change during the ring closure reaction in this step, and therefore, the asymmetric carbon atom of the optically active compound represented by the general formula (5) The configuration of It is taken over as it is.
- the base used when the optically active compound represented by the general formula (5) has the group COR 3 as R 5 is not particularly limited, and the hydroxyl group of the optically active compound represented by the general formula (5) is not particularly limited.
- a base having the ability to remove the above formyl, acyl, or aroyl group is used, for example, alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, and cesium hydroxide, and magnesium hydroxide.
- Alkaline earth metal hydroxides such as calcium hydroxide, barium hydroxide, etc., alkali metal alkoxides such as lithium methoxide, sodium methoxide, potassium ethoxide, sodium isopropoxide, alkalis such as sodium hydrogen carbonate, potassium hydrogen carbonate, etc.
- Al such as metal bicarbonate, lithium carbonate, sodium carbonate, potassium carbonate, etc. Li metal carbonate and the like, preferably sodium hydroxide, potassium carbonate.
- an alcoholic solvent such as methanol, ethanol, propanol, or isopropanol is used as a reaction solvent, it reacts with these to give an alkali metal alkoxide.
- Lithium, sodium, potassium, lithium hydride, sodium hydride Etc. can also be used.
- the amount of the base used depends on the type of the base used, but the lower limit is 10 Omo 1% and the upper limit is 50 Omo 1% for the optically active compound represented by the general formula (5). is there. A preferred lower limit is 11 Omo1%, and a preferred upper limit is 30 Omo1%.
- a solvent is usually used in the reaction, but the solvent is not particularly limited as long as it does not inhibit the reaction.
- the solvent include water, alcohol solvents such as methanol, ethanol, propanol and isopropanol, tetrahydrofuran, and the like.
- examples thereof include ether solvents such as dioxane, and N, N-dimethylformamide. Two or more of the above solvents may be used as a mixture.
- Preferred solvents are alcohol solvents, and methanol is frequently used as a particularly preferred solvent.
- water and solvents that are not compatible with water and do not react with the above base for example, aliphatic hydrocarbon solvents such as hexane and heptane, benzene, toluene, xylene and the like
- the reaction is achieved by combining aromatic hydrocarbon solvents, ether solvents such as ether and methyl tert-butyl ether, and halogenated hydrocarbon solvents such as methylene chloride, chloroform, carbon tetrachloride, and cyclobenzene.
- the reaction may be carried out in a two-phase system solvent. In this case, it is preferable to carry out the reaction by adding a phase transfer catalyst in order to increase the reaction rate.
- phase transfer catalyst examples include aliquat 336, butylpyridinium bromide, benzyltriethylammonium bromide, benzyltriethylammonium chloride, and benzyl chloride.
- the amount of the solvent used is not particularly limited, but the lower limit is the amount of lm 1 and the upper limit is the amount of lOO ml / g for the optically active compound represented by the general formula (5). is there.
- the preferred lower limit is the amount of 2 m1Zg
- the preferred upper limit is the amount of 2Om1Zg.
- the amount of the phase transfer catalyst is not particularly limited, the amount of the catalyst is usually used, and the lower limit is 1 mol% of the optically active compound represented by the general formula (5). Any amount in these ranges can be used, up to a maximum of 10% Omo.
- the reaction temperature varies depending on the type of the solvent used, but usually, any temperature in the range from the freezing point to the boiling point of the reaction solvent can be selected.
- the lower limit is 1 2 0 and the upper limit is 150.
- a preferred lower limit is 0, and a preferred upper limit is 100 ".
- the reaction time varies depending on the type of the optically active compound represented by the general formula (5) used, the reaction solvent and the reaction temperature, but is usually about 0.5 to 24 hours.
- the progress of the reaction can be confirmed by a time-dependent analysis of the reaction solution using ordinary analytical means, for example, high performance liquid chromatography (HPLC), and the optical activity represented by the general formula (5) is obtained.
- HPLC high performance liquid chromatography
- the post-treatment method of the above reaction is not particularly limited, but after the reaction, for example, a saturated aqueous solution of ammonium chloride is added, and the desired product is extracted with an appropriate organic solvent such as ethyl acetate, toluene, benzene, getyl ether, or dichloromethane. Then, the target product can be isolated through operations such as washing of the extraction layer with water or a saturated saline solution, concentration of the solvent, and the like. When the reaction is carried out in a two-phase solvent, it is only necessary to separate water and the organic layer, wash with water if necessary, and concentrate the solvent. If necessary, the purity of the target product may be increased by, for example, purification by column chromatography.
- the base used when R 5 of the optically active compound represented by the general formula (5) is a hydrogen atom is not particularly limited, and examples thereof include lithium hydroxide, sodium hydroxide, and potassium hydroxide.
- Alkali metal hydroxides such as cesium hydroxide, alkaline earth metal hydroxides such as magnesium hydroxide, calcium hydroxide, barium hydroxide, lithium methoxide, sodium methoxide, potassium ethoxide, sodium dimethylisopropoxy
- Alkali metal alkoxides such as sodium chloride, sodium bicarbonate, alkali metal bicarbonate such as potassium bicarbonate, lithium carbonate, sodium carbonate, alkali metal carbonate such as potassium carbonate, lithium, sodium, potassium, lithium hydride, Sodium hydride and the like, preferably potassium carbonate, It is stream methoxide.
- the amount of the base used depends on the type of the base used, but the lower limit is 10 Omo 1% and the upper limit is 50 Omo 1 for the optically active compound represented by the general formula (5). %.
- a preferred lower limit is 11 Omo 1%, and a preferred upper limit is 30 Omo 1%.
- a solvent is usually used for the reaction, but the solvent is not particularly limited as long as it does not inhibit the reaction.
- Also the solvent varies depending on the type of the base used, for example, water, methanol, ethanol Alcohol solvents such as propanol, isopropanol, etc .; ether solvents such as getyl ether, diisopropyl ether, methyl t_butyl ether, tetrahydrofuran, dioxane; aliphatic solvents such as heptane, hexane, cyclohexane, methylcyclohexane, etc.
- Alicyclic hydrocarbon solvents aromatic hydrocarbon solvents such as benzene, toluene, and xylene; ester solvents such as methyl acetate, ethyl acetate, and butyl acetate; ketone solvents such as acetone and ethyl methyl ketone; methylene chloride; 1,2-dichloroethane, M
- Halogenated hydrocarbon solvents such as benzene, carbon tetrachloride, and chlorobenzene; nitrile solvents such as acetonitrile, propionitrile, and benzonitrile; N, N-dimethylformamide; and N, N-dimethylacetamide. It is also possible to use a mixture of two or more of the above solvents. For example, when potassium carbonate is used as the base, alcohol-based / ketone-based solvents are often used as preferred solvents.
- the reaction temperature varies depending on the type of the solvent used, but usually, any temperature in the range from the freezing point to the boiling point of the reaction solvent can be selected. Generally, the lower limit is 1-2Ot: and the upper limit is 150. A preferred lower limit is 0 and a preferred upper limit is 100.
- the reaction time varies depending on the type of the optically active compound represented by the general formula (5) used, the reaction solvent and the reaction temperature, but is usually about 0.5 to 72 hours.
- the progress of the reaction can be confirmed by a time-dependent analysis of the reaction solution using ordinary analytical means, for example, high performance liquid chromatography (HPLC), and the optical activity represented by the general formula (5) is obtained.
- HPLC high performance liquid chromatography
- the post-treatment method for the above reaction is not particularly limited, but after the reaction, for example, water is added to the reaction solution to stop the reaction, and ethyl acetate, toluene, benzene, getyl are added.
- the desired product can be isolated by extracting the desired product with an appropriate organic solvent such as ether or dichloromethane, washing the extracted layer with water or a saturated saline solution, and concentrating the solvent. If necessary, the purity of the target product may be increased by, for example, purification by column chromatography.
- HPLC high performance liquid chromatography
- Example 1 2 Production of (2 R / S, 4 S) -4-[(N-benzyloxycarbonyl) aminomethyl] 1, 1,3,2 ⁇ 4 -dioxathiolan-2-one
- Compound (4 ) Manufacturing of] (S) 11- (N-benzyloxycarbonyl) amino-2,3-propanediol 2.068 g (9.18 mmo 1) was dissolved in 40 ml of porcine, and chlorinated under ice-cooling.
- Thionyl 2.85 g (23.8 mmo and 26 Omo 1%) was added dropwise over 10 minutes, and 3.72 g (36.7 mmol, 40 Omo 1%) of triethylamine was added over 15 minutes. And dropped.
- the reaction mixture was added to 30 ml of water containing 2 ml of 4N hydrochloric acid at room temperature, and 10 ml of methylene chloride was added for extraction and separation.
- the aqueous layer was extracted once more with 20 ml of methylene chloride, and the whole organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- the resulting oil was purified by silica gel column chromatography (eluent: ethyl acetate).
- the dropping funnel containing the pyridine was washed with 5 ml of dichloride, and the mixture was stirred at the same temperature for 1 hour and at room temperature for 15 hours.
- To the reaction mixture was added 50 ml of water containing 0.5 ml of concentrated hydrochloric acid at room temperature, and the mixture was extracted and separated.
- the reaction was quenched by adding 10 ml of a saturated aqueous sodium hydrogen carbonate solution, extracted three times with 10 ml of ethyl acetate, and the whole organic layer was washed once with 30 ml of a saturated saline solution and dried over anhydrous magnesium sulfate. The organic layer was concentrated under reduced pressure and dried under vacuum to obtain 440 mg of a crude product.
- Example 1 2 (2 RZS, 4 S ) - 4 - [(N_ benzyl O carboxymethyl Cal Poniru) aminomethyl] one 1, 3, 2 ⁇ 4 - Jiokisachioran - 2-one 2.
- 1 2 g was dissolved in 40 ml of dimethylformamide, and 1.56 g (36.7 mmo1, 40 Omo ⁇ %) of lithium chloride was added thereto under ice-cooling, followed by stirring at 80 for 12 hours. After cooling to room temperature, 20 ml of 1N hydrochloric acid was added to stop the reaction. Ethyl acetate was extracted three times with 40 ml, and the whole organic layer was washed three times with 100 ml of water and saturated saline.
- Example 1 6 (2R / S, 4 S) -4 one (N- benzo I Le amino methylation) one 1, 3, 2 ⁇ 4 - Jiokisachioran one 2 _ on 41 7. tetra 1 mg Dissolve in 15 ml of hydrofuran and add 615 mg of lithium bromide (7.
- 41 g was dissolve in acetone 70 m 1, at room temperature Then, 3.6 g (41.45 mmol, 357 mol) of lithium bromide was added, and the mixture was refluxed and stirred for 9 hours. The reaction mixture was cooled to room temperature, and the solvent was distilled off under reduced pressure. To the concentrate, 40 ml of water containing 2 ml of concentrated hydrochloric acid was added, and extracted with 50 ml of ethyl ether.
- Acetic acid (S) —2- (N-benzyloxycarponyl) amino-1- (chloromethyl) ethyl obtained in the same manner as in Example 19 2.43 g (8.45 mmo 1) of methanol 25 m 1 And 2.50 g of potassium carbonate (17.00 mmol, 20 Omo 1%) was added thereto, followed by stirring at room temperature for 2 hours. 20 ml of a saturated aqueous solution of ammonium chloride was added to the reaction solution, extracted with 20 ml of ethyl acetate, and the organic layer was washed with 20 ml of a saturated saline solution.
- Butyric acid (S) —2- (N-benzyloxycarbonyl) amino-11- (chloromethyl) ethyl obtained in Example 20 (168 mg, 0.535 mmol) was added to 2 ml of methanol. After dissolving, 90.2 mg (0.652 mmo 12 Omo 1%) of potassium carbonate was added, and the mixture was stirred at room temperature for 3 hours. 5 ml of a saturated aqueous solution of ammonium chloride was added to the reaction solution, and the mixture was extracted twice with 10 ml of ethyl acetate, and the whole organic layer was washed with 20 ml of saturated saline.
- Example 31 1.43 g (38.9 lmmo 1) of a toluene solution of acetic acid (R) —2- (N-benzyloxycarponyl) amino-1- (chloromethyl) ethyl obtained in the same manner as in Example 1 was dissolved in 11 ml of methanol, and 42 ml (42 mmo 1, 108 mol 1%) of a methanol solution of Imol Zl sodium methoxide Z was added dropwise under ice-cooling. After the completion of the dropwise addition, the mixture was stirred for 4.5 hours. 0.3 ml of acetic acid was added to the reaction solution to stop the reaction, and the solvent was concentrated under reduced pressure.
- acetic acid (R) —2- (N-benzyloxycarponyl) amino-1- (chloromethyl) ethyl obtained in the same manner as in Example 1 was dissolved in 11 ml of methanol, and 42 ml (42 mmo 1, 108 mol 1
- the optical purity analysis was performed under the following conditions.
- the present invention has the above-described constitution, it is possible to efficiently and industrially advantageously produce optically active monosubstituted amino-2,3-epoxypropane useful as an intermediate for producing agricultural chemicals, pharmaceuticals, and the like. Further, a novel synthetic intermediate for producing the optically active epoxy propane is provided.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/518,012 US20050215801A1 (en) | 2002-06-28 | 2003-06-17 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates |
JP2004517257A JPWO2004002973A1 (ja) | 2002-06-28 | 2003-06-17 | 光学活性1−置換アミノ−2,3−エポキシプロパンの製造方法並びにその合成中間体およびそれらの製造方法 |
EP03761764A EP1553093A1 (en) | 2002-06-28 | 2003-06-17 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for the synthesis thereof and process for preparation of the intermediates |
AU2003244235A AU2003244235A1 (en) | 2002-06-28 | 2003-06-17 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for the synthesis thereof and process for preparation of the intermediates |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002189796 | 2002-06-28 | ||
JP2002-189796 | 2002-06-28 | ||
JP2002-306445 | 2002-10-22 | ||
JP2002-306444 | 2002-10-22 | ||
JP2002306444 | 2002-10-22 | ||
JP2002306445 | 2002-10-22 | ||
JP2002-362343 | 2002-12-12 | ||
JP2002362343 | 2002-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004002973A1 true WO2004002973A1 (ja) | 2004-01-08 |
Family
ID=30003907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/007695 WO2004002973A1 (ja) | 2002-06-28 | 2003-06-17 | 光学活性1−置換アミノー2,3−エポキシプロパンの製造方法並びにその合成中間体およびそれらの製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050215801A1 (ja) |
EP (1) | EP1553093A1 (ja) |
JP (1) | JPWO2004002973A1 (ja) |
AU (1) | AU2003244235A1 (ja) |
WO (1) | WO2004002973A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005306803A (ja) * | 2004-04-23 | 2005-11-04 | Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai | 不飽和化合物の酸化方法 |
JP2007297305A (ja) * | 2006-04-28 | 2007-11-15 | Daiso Co Ltd | N−(2,3−エポキシ−2−メチルプロピル)フタルイミドの製造法 |
JP2008120704A (ja) * | 2006-11-09 | 2008-05-29 | Emcure Pharmaceuticals Ltd | β遮断薬化合物の改善された調製方法 |
WO2013068948A1 (en) | 2011-11-08 | 2013-05-16 | Actelion Pharmaceuticals Ltd | 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives |
WO2013122185A1 (ja) * | 2012-02-16 | 2013-08-22 | 花王株式会社 | エポキシ化合物の製造方法 |
JP2014513115A (ja) * | 2011-05-06 | 2014-05-29 | エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ | リバロキサバンの製法及び該方法において形成される中間体 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999052855A1 (en) * | 1998-04-14 | 1999-10-21 | Samsung Fine Chemicals Co., Ltd. | A process for preparing chiral (s)-2,3-disubstituted-1-propylamine derivatives |
WO1999062861A1 (en) * | 1998-06-01 | 1999-12-09 | Michigan State University | Process for the preparation of protected 3-amino-1,2-dihydroxypropane acetal and derivatives thereof |
WO2002032857A1 (en) * | 2000-10-17 | 2002-04-25 | Pharmacia & Upjohn Company | Methods of producing oxazolidinone compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4202978A (en) * | 1978-02-08 | 1980-05-13 | Hoffmann-La Roche Inc. | (S)-1-[2-(4-(2-Hydroxy-s-(1-alkylaminopropoxy)phenylalkyl]-4-phenylpiperazines |
US4371704A (en) * | 1978-06-29 | 1983-02-01 | Texaco Development Corporation | Substituted alkylene oxides from substituted alkylene carbonates |
US4304721A (en) * | 1979-09-06 | 1981-12-08 | Hoffmann-La Roche Inc. | Adrenergic blocking agents |
ZA98900B (en) * | 1997-02-07 | 1998-08-03 | Shell Int Research | Process for the manufacture of epoxy compounds |
EP1052257B1 (en) * | 1998-01-28 | 2004-03-31 | Nippon Kayaku Kabushiki Kaisha | Process for producing optically active threo-3-amino-1,2-epoxy compounds |
-
2003
- 2003-06-17 WO PCT/JP2003/007695 patent/WO2004002973A1/ja not_active Application Discontinuation
- 2003-06-17 AU AU2003244235A patent/AU2003244235A1/en not_active Abandoned
- 2003-06-17 US US10/518,012 patent/US20050215801A1/en not_active Abandoned
- 2003-06-17 EP EP03761764A patent/EP1553093A1/en not_active Withdrawn
- 2003-06-17 JP JP2004517257A patent/JPWO2004002973A1/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999052855A1 (en) * | 1998-04-14 | 1999-10-21 | Samsung Fine Chemicals Co., Ltd. | A process for preparing chiral (s)-2,3-disubstituted-1-propylamine derivatives |
WO1999062861A1 (en) * | 1998-06-01 | 1999-12-09 | Michigan State University | Process for the preparation of protected 3-amino-1,2-dihydroxypropane acetal and derivatives thereof |
WO2002032857A1 (en) * | 2000-10-17 | 2002-04-25 | Pharmacia & Upjohn Company | Methods of producing oxazolidinone compounds |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005306803A (ja) * | 2004-04-23 | 2005-11-04 | Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai | 不飽和化合物の酸化方法 |
JP2007297305A (ja) * | 2006-04-28 | 2007-11-15 | Daiso Co Ltd | N−(2,3−エポキシ−2−メチルプロピル)フタルイミドの製造法 |
JP2008120704A (ja) * | 2006-11-09 | 2008-05-29 | Emcure Pharmaceuticals Ltd | β遮断薬化合物の改善された調製方法 |
JP2014513115A (ja) * | 2011-05-06 | 2014-05-29 | エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ | リバロキサバンの製法及び該方法において形成される中間体 |
WO2013068948A1 (en) | 2011-11-08 | 2013-05-16 | Actelion Pharmaceuticals Ltd | 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives |
US9079922B2 (en) | 2011-11-08 | 2015-07-14 | Actelion Pharmaceuticals Ltd | 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives |
WO2013122185A1 (ja) * | 2012-02-16 | 2013-08-22 | 花王株式会社 | エポキシ化合物の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004002973A1 (ja) | 2005-10-27 |
AU2003244235A1 (en) | 2004-01-19 |
US20050215801A1 (en) | 2005-09-29 |
EP1553093A1 (en) | 2005-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1840125B1 (fr) | Intermédiaires pour la production de dioxane-2-alkylcarbamates | |
HUE027872T2 (en) | A novel process for statins and their pharmaceutically acceptable salts | |
WO1998009949A1 (fr) | Nouveaux derives d'acetamide et inhibiteurs de protease | |
JP5001831B2 (ja) | α−ヒドロキシ−ω−グリシジルエーテルの製造方法 | |
WO2006080555A1 (ja) | (z)-1-フェニル-1-(n,n-ジエチルアミノカルボニル)-2-フタルイミドメチルシクロプロパンの製造方法 | |
KR20050019764A (ko) | 에폭시트리아졸 유도체 및 그에 대한 중간체를 제조하는방법 | |
WO2004002973A1 (ja) | 光学活性1−置換アミノー2,3−エポキシプロパンの製造方法並びにその合成中間体およびそれらの製造方法 | |
JP6222973B2 (ja) | ジベンジルトリチオカーボネート誘導体 | |
RU2470018C2 (ru) | Новые производные пирокатехина | |
AU717637B2 (en) | Production of amide derivatives and intermediates therefor | |
CN100363355C (zh) | 制备烷氧基呋喃酮胺衍生物的方法、通过该方法得到的化合物和这些化合物的用途 | |
EP0930291B1 (en) | Process for the preparation of 3-amino-2-hydroxy-1-propyl ethers | |
JPH05221938A (ja) | 置換アミノプロパン、それらの製造方法およびそれらの使用 | |
WO1998012186A1 (fr) | Procede de preparation d'ethers glycidyliques | |
KR100418327B1 (ko) | 신규의 아지리딘 유도체 및 그 제조방법 | |
JP5338072B2 (ja) | 4−ハロカテコール化合物の製法 | |
US20060155136A1 (en) | Optically active halohydrin derivative and process for producing optically active epoxy alcohol derivative from the same | |
Takano et al. | An enantio-and stereo-controlled synthesis of L-erythro-and D-threo-C18-sphingosines via the anomalous version of the katsuki–sharpless asymmetric epoxidation reaction | |
JPH03167167A (ja) | 3,4―エポキシ酪酸エステルの製法および中間体 | |
JP4001388B2 (ja) | 3―アミノ―2―ヒドロキシ―1―プロピルエーテルの製造法 | |
ES2364659T3 (es) | Derivado de halohidrina ópticamente activo y proceso para producir un derivado de epoxi alcohol ópticamente activo a partir del mismo. | |
JP4259743B2 (ja) | ケタール化合物の製造方法 | |
Lohray et al. | Nucleophilic reaction of glycidol tosylate and the corresponding cyclic sulphate with various nucleophiles: A comparative study ǂ | |
WO2002024671A1 (en) | Process for preparing optically active epoxides | |
CN109293508A (zh) | 一种恩替卡韦中间体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004517257 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10518012 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003761764 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003761764 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003761764 Country of ref document: EP |